On Jun. 11, 2020, Emergent BioSolutions announced deployment of its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZenecaﾒs vaccine candidate for COVID-19, AZD1222, a viral vector-based, weakened version of adenovirus containing the genetic material of SARS-CoV-2 spike protein, developed by Oxford Universityﾒs Jenner institute working with the Oxford Vaccine Group.